Opna Bio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OPN-2853 / Opna Bio
2020-002021-28: A Study to Evaluate PLX2853 in Combination with Abiraterone Acetate/Prednisone and PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
1/2
110
Europe
PLX2853, Abiraterone Acetate, Prednisolone, PLX2853, Tablet, ZYTIGA, PREDNISOLONE
Plexxikon Inc., Plexxikon Inc.
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Resistant Prostate Cancer, Diseases [C] - Cancer [C04]
 
 
NCT05677373: Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Withdrawn
1/2
54
NA
BRD4 Inhibitor PLX2853, PLX 2853, PLX-2853, PLX2853, Trametinib, 871700-17-3, GSK1120212, JTP-74057, Computed Tomography, CAT, CAT scan, Computed Axial Tomography, CT Scan, Magnetic Resonance Imaging, MRI, Biospecimen collection
Alliance for Clinical Trials in Oncology
Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma
07/25
07/25
2019-000916-27: A study investigating the combination of two drugs (PLX2853 and ruxolitinib) in patients with intermediate-2 or high risk myelofibrosis who are not receiving an adequate response with ruxolitinib alone.

Not yet recruiting
1
60
Europe
PLX2853, Jakavi, Tablet, Jakavi
University of Birmingham
Myelofibrosis, Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
OPN-6602 / Opna Bio
OPN6602-C01, NCT06433947: Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Recruiting
1
130
US
OPN-6602, Dexamethasone
Opna Bio LLC
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
07/26
07/26
OPN-9627 / Opna Bio
No trials found
OPN-9840 / Opna Bio
No trials found
OPN-FMRP / Opna Bio
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OPN-2853 / Opna Bio
2020-002021-28: A Study to Evaluate PLX2853 in Combination with Abiraterone Acetate/Prednisone and PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
1/2
110
Europe
PLX2853, Abiraterone Acetate, Prednisolone, PLX2853, Tablet, ZYTIGA, PREDNISOLONE
Plexxikon Inc., Plexxikon Inc.
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Resistant Prostate Cancer, Diseases [C] - Cancer [C04]
 
 
NCT05677373: Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Withdrawn
1/2
54
NA
BRD4 Inhibitor PLX2853, PLX 2853, PLX-2853, PLX2853, Trametinib, 871700-17-3, GSK1120212, JTP-74057, Computed Tomography, CAT, CAT scan, Computed Axial Tomography, CT Scan, Magnetic Resonance Imaging, MRI, Biospecimen collection
Alliance for Clinical Trials in Oncology
Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma
07/25
07/25
2019-000916-27: A study investigating the combination of two drugs (PLX2853 and ruxolitinib) in patients with intermediate-2 or high risk myelofibrosis who are not receiving an adequate response with ruxolitinib alone.

Not yet recruiting
1
60
Europe
PLX2853, Jakavi, Tablet, Jakavi
University of Birmingham
Myelofibrosis, Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
OPN-6602 / Opna Bio
OPN6602-C01, NCT06433947: Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Recruiting
1
130
US
OPN-6602, Dexamethasone
Opna Bio LLC
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
07/26
07/26
OPN-9627 / Opna Bio
No trials found
OPN-9840 / Opna Bio
No trials found
OPN-FMRP / Opna Bio
No trials found

Download Options